preventive cardiology: aspirin, omega-3, and lipid therapyan lp(a) ≥50 mg/dl or ≥125 nmol/l...
TRANSCRIPT
-
Preventive Cardiology: Aspirin, Omega-3, and Lipid Therapy
• Update in Internal Medicine: Advance Changing Practice
• Aryan Aiyer, MD• Assistant Professor of Medicine, UPSOM• Director, Lipid Clinic, UPMC HVI• Director, Inpatient Cardiology Consult Service, UPMC Presbyterian
-
No Disclosures Related to this Talk
-
Objectives
• Follow the 2018 update to the ACC/AHA Blood Cholesterol guidelines in order to improve identification of those patients that may benefit most from aggressive lipid intervention
• Improve patient outcomes by reviewing recent data regarding the use of aspirin in primary prevention
• Implement precision based risk assessment in daily practice so as to improve identification of primary prevention patients who may benefit from statin therapy
-
Guidelines
-
Evolution of NHLBI Supported Guidelines
Angiographic trials (FATS, POSCH, SCOR, STARS, Ornish, MARS)Meta-analyses(Holme, Rossouw)
NCEP ATP I1988
NCEP ATP II1993
NCEP ATP III2001
HPSPROVE-ITASCOT-LLAPROSPERALLHAT-LLT
NCEP ATP IIIUpdate 2004
FraminghamMRFITLRC-CPPTCoronaryDrug Project
Helsinki HeartCLAS
4SWOSCOPSCARELIPIDAFCAPS/TexCAPS
TNTIDEAL
AHA/ACC Update2006
More Intensive Treatment Recommendations
-
Evolution of NHLBI Supported Guidelines
AHA/ACC 2013
AHA/ACC2018
Therapy based on risk status using risk calculator (PCE)
IMPROVE ITFOURIERODYSSEY
MESA
“Know your risk” “Know your risk and levels”
-
Secondary Prevention
-
Intensity of Statin Therapy
*Individual responses to statin therapy varied in the RCTs and should be expected to vary in clinical practice. There might be a biologic basis for a less-than-average response. †Evidence from 1 RCT only: down-titration if unable to tolerate atorvastatin 80 mg in IDEAL (Pedersen et al).‡Although simvastatin 80 mg was evaluated in RCTs, initiation of simvastatin 80 mg or titration to 80 mg is not recommended by the FDA due to the increased risk of myopathy, including rhabdomyolysis.
2018 ACC Blood Cholesterol Guidelines
-
Risk-Enhancing Factors
• Family history of premature ASCVD (males, age
-
Risk-Enhancing Factors
• Lipid/biomarkers: Associated with increased ASCVD risko Persistently* elevated, primary hypertriglyceridemia (≥175 mg/dL);o If measured:
§ Elevated high-sensitivity C-reactive protein (≥2.0 mg/L)§ Elevated Lp(a): A relative indication for its measurement is family history
of premature ASCVD. An Lp(a) ≥50 mg/dL or ≥125 nmol/L constitutes a risk-enhancing factor especially at higher levels of Lp(a).
§ Elevated apoB ≥130 mg/dL: A relative indication for its measurement would be triglyceride ≥200 mg/dL. A level ≥130 mg/dL corresponds to an LDL-C >160 mg/dL and constitutes a risk-enhancing factor
§ ABI
-
Case Examples
-
Case 1
23 year old woman comes in for well visit
No meds or past history
Non-smoker, vegan, yoga
Mother had MI at 59
PE and vitals are normal
Labs: Chol 320, HDL 55, TG 135, LDL 238
What do we do?
-
Case 2
60 year old white man here to establish care after job move
No PMHx, meds
Non-smoker, no exercise
Father had MI at age 80
PE: BMI 25, BP 136/78
Labs: Chol 221, HDL 55, TG 133, LDL 140
Calculated 10-year ASCVD risk…9.8%
What do we do?
-
How can coronary calcium measurement help guide clinical decision-making?
-
Implications of Coronary Calcium Testing Among Statin Candidates
• Multi-ethnic Study of Atherosclerosis (MESA)• 6814 subjects without ASCVD at
enrollment• Ages 45-84• 6 centers in the US for enrollment
(NYC, LA, Chicago, Baltimore, St. Paul, MN, and Forsyth County, NC• Self-identified race/ethnicity
18
-
Implications of Coronary Calcium Testing Among Statin Candidates
• Aim was to see how CAC reclassifies ASCVD risk• Excluded the following
• Age > 75• Missing LDL levels and LDL < 70• Already on lipid lowering
medication• Missing variables so that ASCVD
risk couldn’t be calculated• Total remaining cohort of 4758 subjects
19
-
Impact of the Absence of CAC in Reclassifying Risk Below Threshold for Statin Consideration
-
Case 2 (cont’d)
Risk Discussion
Patient was averse to taking a statin
Agreed to have a coronary calcium scan
CAC score = 0
Based on this result, no statin was initiated as it re-classified the patient’s risk to a lower level.
Lifestyle measures recommended (e.g. exercise, diet)
-
Case 3
22
48 year old male of South Asian descent
• History of mixed dyslipidemia (↓HDL, ↑TG)• Prediabetes
Medical History:
No meds
• Little formal exercise• Indian food, non-vegetarian
Lifestyle
-
Case 3 (cont’d)
23
Strong Family history of Heart Disease• Father had MI at 50• Mother had CABG at 60• Paternal uncle had CABG in his 50s• Both parents and sister have gestational diabetes
Physical Exam: 163 lbs, BMI 23, BP 135/85
Lipids: Chol 203, LDL 127, HDL 32, TG 220
Hgb A1C 6.3
Calculated 10-year ASCVD Risk….5.2%
What do we do?
-
Case 3 (cont’d)
Risk Enhancers• Ethnicity (South Asian background)• Metabolic syndrome• Family History• Persistently elevated triglycerides
Recommendations• Change lifestyle• Consider starting a statin (Class IIb level of
evidence)
Patient reluctant to take meds
Do we do anything else?
-
Case 3 (cont’d)
Coronary calcium assessment
CAC score = 481
After these results, he agreed to start a statin
-
Impact of Statins on CV outcomes after CAC scoring
• Retrospective analysis of consecutive subjects without ASCVD at Walter Reed Medical Center from 2002-2009 who underwent CAC scans
• Statin use monitored by filled prescriptions• Sought to determine whether CAC could
predict which patients would benefit the most from statins
• 13644 patients (mean age 50, 71% men)• Median follow up of 9.4 years• Primary Outcome was MACE: composite
of MI, stroke, or cardiovascular death
27
-
Impact of Statins on CV outcomes after CAC scoring
28
Joshua D. Mitchell et al. JACC 2018;72:3233-3242
-
Joshua D. Mitchell et al. JACC 2018;72:3233-3242
-
Case 4
72 year old diabetic with recent NSTEMI 3 months ago
PCI to LAD. Non-obstructive CAD elsewhere
Uncomplicated hospital course
Discharged on standard post-MI meds
aspirin, clopidogrel, B-blocker, ACE-inhibitor
High intensity statin (Atorvastatin 80 mg po qd)
Cardiac rehab referral
-
Case 4 (cont’d)
Physical exam: BP 122/78, HR 62,
BMI 27
Lipids: Chol 150, LDL 85, HDL 40,
TG 125,
HgbA1C: 6.7
What should we do?
-
Secondary Prevention
-
Aspirin
-
Use of Aspirin for Primary PreventionUSPSTF Update in 2016
Population Recommendation GradeAge 50-59>10% 10-year CVD Risk
Low dose aspirinLow bleeding riskShould take for 10 yearsLife expectancy of at least 10 years
B
Age 60-69>10% year CVD Risk
Low dose aspirinLow bleeding riskShould take for 10 yearsLife expectancy of at least 10 years
C
Age < 50 IAge > 70 I
-
Recommendations of Other Groups (2018)
AHA/ACC 10-year ASCVD Risk threshold of 6% threshold
American College of Chest Physicians
Age over 50
American Academy of Family Physicians
USPSTF guidelines
American Diabetes Association
> 10% 10-year ASCVD risk
European Society of Cardiology
Don’t use aspirin for primary prevention (class III)
-
Recent Prevention Trials with Aspirin
Trial Primary Endpoints/Events Adverse Events (Primary safety outcome)
ASCEND
N = 15,480
Diabetics
ASA 100 mg
Mean F/U 7.4 years
First serious Vascular event
• CV death• Nonfatal MI or Stroke or TIA
Major bleeding
• Intracranial hemorrhage• GI• Bleeding requiring Hospitalization or
transfusion
ARRIVE
N = 12,546
Intended to enroll high risk w/o DM
ASA 100 mg
Median F/U 5 years
First serious Vascular event
• CV death• Nonfatal MI or Stroke or TIA• Unstable angina
Hemorrhagic events
ASPREE
N=19,114
Age > 70 years
ASA 100 mg
Median F/U 4.7 years
Composite primary endpoint
• Death• Dementia• Physical DisabilitySecondary Endpoint - MACE
Major Hemorrhage
• Hemorrhagic stroke• Symptomatic intracranial bleeding• Extracranial bleeding requiring
hospitalization or transfusion
-
Recent Prevention Trials with Aspirin
Trial Primary Endpoints/Events Adverse Events (Primary safety outcome)
ASCENDN = 15,480, Diabetics, UK populationmean age 63, 96% white, 63% male47% obese, 76% on statinsMean F/U 7.4 years
First Serious Vascular Event:ASA 8.5%Placebo 9.6%RR 0.88; CI 0.79-0.97, P=0.01
Major Hemorrhage:ASA 4.1%Placebo 3.2%RR 1.29; CI 1.09-1.52, P=0.003
ARRIVEN = 12,546, estimated high risk w/o DM> 93% European, 28% smokersMean age 64, 98% white, 70% maleMedian F/U 5 years
First Serious Vascular Event:ASA 4.3%Placebo 4.5%HR 0.96; CI 0.81-1.13, P=0.6(Event rates lower than expected)
GI Bleeding Events:ASA 3.28%Placebo 1.36%HR 2.1; CI 1.36-3.28, P
-
PM Ridker. N Engl J Med 2018;379:1572-1574.
Aspirin and All-Cause Mortality in 14 Primary Prevention Trials.
-
2019 ACC/AHA Guidelines on the Primary Prevention of CVD
• “Aspirin should be used infrequently in the routine primary prevention of ASCVD because of the lack of net benefit.”
-
Omega-3 PUFA
Conditions postulated to benefit from fish oils• Severe Hypertriglyceridemia• Primary prevention• Heart Failure• Stroke• Atrial Fibrillation• Secondary prevention from
prior MI or ASCVD
-
2017 AHA Science Advisory
Siscovick et.al. Circulation 2017;135:e867-884
Secondary prevention
• Coronary heart disease and sudden cardiac death among patients with prevalent CAD – IIa recommendations
• Secondary prevention in patients with heart failure – IIa
• No benefit to prevent recurrent stroke or AFib
Primary prevention – no benefit (Class III)
-
REDUCE IT Trial
-
Summary
• In very high risk ASCVD patients…• goal of LDL less than 70 mg/dl and non-
HDL less than 100 mg• non-statin drugs such as ezetimibe and
PCSK9 inhibitors may be reasonable• Risk enhancers and coronary calcium
assessment may be useful to further risk stratify those in the intermediate risk range
• Recent clinical trials have shown limited to no CV benefit of aspirin for primary prevention while there is consistent risk of bleeding
• EPA may be the preferred Omega-3 PUFA. Use for secondary prevention in high risk patients with residual TG elevation may be useful. Jury is still out for primary prevention in general population.